KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Equity Average (2016 - 2025)

Historic Equity Average for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Q3 2025 value amounting to $17.2 billion.

  • Vertex Pharmaceuticals' Equity Average rose 1344.69% to $17.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 billion, marking a year-over-year increase of 1344.69%. This contributed to the annual value of $17.0 billion for FY2024, which is 792.84% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Equity Average stood at $17.2 billion, which was up 1344.69% from $16.8 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Equity Average high stood at $18.1 billion for Q1 2024, and its period low was $8.8 billion during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $15.0 billion (2023), whereas its average is $13.9 billion.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Equity Average soared by 4080.9% in 2021, and later tumbled by 891.6% in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Equity Average stood at $9.8 billion in 2021, then surged by 37.25% to $13.5 billion in 2022, then rose by 26.54% to $17.0 billion in 2023, then dropped by 6.02% to $16.0 billion in 2024, then rose by 7.66% to $17.2 billion in 2025.
  • Its Equity Average was $17.2 billion in Q3 2025, compared to $16.8 billion in Q2 2025 and $16.5 billion in Q1 2025.